We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+12.49%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$410M
(+23%)
Cap. Flow
+$230M
Cap. Flow
% of AUM
10.53%
Top 10 Holdings %
Top 10 Hldgs %
65.42%
Holding
52
New
13
Increased
11
Reduced
11
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$246M |
| 2 |
Edwards Lifesciences
EW
|
+$117M |
| 3 |
AET
Aetna Inc
AET
|
+$92.4M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$90.2M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$88.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$99.7M |
| 2 |
QGENF
QIAGEN NV
QGENF
|
+$79.9M |
| 3 |
Danaher
DHR
|
+$74.4M |
| 4 |
Incyte
INCY
|
+$74.3M |
| 5 |
Zimmer Biomet
ZBH
|
+$69.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.1% |
| 2 | Financials | 9.22% |
| 3 | Materials | 1.56% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Medpace
MEDP
$16.1B
| $20.9M | 0.96% |
700,000
+275,000
| +65% | +$8.88M |
|
|
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
| $19.1M | 0.88% |
300,000
-325,000
| -52% | -$19.8M |
|
28
DexCom
DXCM
$28.8B
| $19.1M | 0.87% |
900,000
-614,600
| -41% | -$12M |
|
|
BCR
29
DELISTED
CR Bard Inc.
BCR
| $19M | 0.87% |
76,560
-30,810
| -29% | -$7.43M |
|
30
Medtronic
MDT
$110B
| $17.2M | 0.79% |
+213,030
| New | +$16.6M |
|
|
AKRX
31
DELISTED
Akorn Inc
AKRX
| $15.7M | 0.72% |
+650,000
| New | +$14.1M |
|
32
Cigna
CI
$76.1B
| $14.8M | 0.68% |
100,720
-329,420
| -77% | -$48.5M |
|
|
JUNO
33
DELISTED
Juno Therapeutics, Inc.
JUNO
| $11.7M | 0.53% |
+525,000
| New | +$11.3M |
|
|
34
Danaher
DHR
$138B
| $10.1M | 0.46% |
133,307
-999,938
| -88% | -$74.4M |
|
|
35
Quest Diagnostics
DGX
$25.9B
| $7.75M | 0.36% |
78,982
-1,046,018
| -93% | -$99.7M |
|
36
Becton Dickinson
BDX
$45.6B
| $4.5M | 0.21% |
+25,174
| New | +$4.39M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.7B
| – | – |
-775,000
| Closed | -$64.2M |
|
38
Collegium Pharmaceutical
COLL
$1.17B
| – | – |
-1,426,300
| Closed | -$22.2M |
|
39
Encompass Health
EHC
$11B
| – | – |
-1,257,659
| Closed | -$41.3M |
|
|
FOLD
40
CALL
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-500,000
| Closed | -$2.48M |
|
41
CALL
Gilead Sciences
GILD
$163B
| – | – |
-350,000
| Closed | -$25.1M |
|
42
Globus Medical
GMED
$10.9B
| – | – |
-450,000
| Closed | -$11.2M |
|
|
HOLX
43
DELISTED
Hologic
HOLX
| – | – |
-452,340
| Closed | -$18.1M |
|
|
44
Incyte
INCY
$24.9B
| – | – |
-741,360
| Closed | -$74.3M |
|
45
Natera
NTRA
$38.6B
| – | – |
-299,300
| Closed | -$3.5M |
|
46
Revvity
RVTY
$12.7B
| – | – |
-44,150
| Closed | -$2.3M |
|
47
Thermo Fisher Scientific
TMO
$214B
| – | – |
-94,980
| Closed | -$13.4M |
|
|
48
Zimmer Biomet
ZBH
$18.4B
| – | – |
-695,003
| Closed | -$69.6M |
|
|
SPNE
49
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| – | – |
-641,700
| Closed | -$5.07M |
|
|
PRAH
50
DELISTED
PRA Health Sciences, Inc.
PRAH
| – | – |
-300,000
| Closed | -$16.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2017 Portfolio in Review
As of Q1 2017, HealthCor Management held 52 positions worth $2.18B, up 23% from $1.77B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
HealthCor Management deployed $230M of net new capital in Q1 2017, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 5,000,000 shares worth $272M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 81% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Quest Diagnostics, an estimated $99.7M trimmed.
- HealthCor Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 5,000,000 shares worth $272M.
- HealthCor Management added most to Aetna Inc in Q1 2017, an estimated $92.4M increase.
- HealthCor Management's biggest Q1 2017 reduction was Quest Diagnostics, cutting an estimated $99.7M.
- HealthCor Management fully exited QIAGEN NV in Q1 2017, selling an estimated $79.9M.
- HealthCor Management's ten largest holdings make up 65% of its $2.18B portfolio in Q1 2017.
- HealthCor Management opened 13 new positions and closed 16 in Q1 2017.
- HealthCor Management's portfolio value rose 23% quarter-over-quarter to $2.18B.
Based on HealthCor Management's 13F filing for Q1 2017, filed 15 May 2017.